Richard Yeh

Citi

First-place appearances: 0 Total appearances: 3 Analyst debut: 2011

Meriting second-place honors for a third consecutive year is Richard Yeh. Among the stocks the Citi analyst favors is Hong Kong–based CSPC Pharmaceutical Group, which he has urged investors to buy since January. In 2012, CSPC’s management announced a shift in focus from manufacturing active pharmaceuticals ingredients — such as cephalosporins, penicillins and vitamins — to researching and developing differentiated pharmaceuticals, with the aim of establishing an R&D pipeline sufficiently robust to sustain long-term gains. Yeh praised the strategy and noted as well that strong growth momentum for the company’s leading drugs would help drive expansion beyond 2015. The stock had bounded ahead 78.2 percent, to HK$4.83, by the end of October, outdistancing the sector by 79.1 percentage points. — Katie Gilbert